statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gagnants
Le titre IN8bio (NASDAQ:INAB) a augment mardi de 31,19% 1,43 dollars lors de la session after-market.
L'action ImmuCell (NASDAQ:ICCC) a grimp de 11,11% 5,80 dollars.
L'action aTyr...

12 titres de soins de sant  en mouvement lors de la session apr s-cl ture le 09/04/2024

SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its...

aTyr Pharma to Participate in April Investor Conferences

Q4 2023 aTyr Pharma Inc Earnings Call Transcript

aTyr Pharma, Inc. (LIFE) Q4 2023 Earnings Call Transcript...

aTyr Pharma, Inc. (LIFE) Q4 2023 Earnings Call Transcript

Enrollment for Phase 3 EFZO-FIT Study Advances with Strong Cash PositionRelated Stocks: LIFE...

aTyr Pharma Inc (LIFE) Reports Full Year 2023 Financial Results and Corporate Progress

Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis anticipated to complete enrollment in the second quarter of 2024. Company launches Individual Patient Expanded Access Program...

aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

Key Insights Given the large stake in the stock by institutions, aTyr Pharma's stock price might be vulnerable to their...

Institutional investors may adopt severe steps after aTyr Pharma, Inc.'s (NASDAQ:LIFE) latest 11% drop adds to a year losses

Management to host conference call and webcast on March 14th at 5:00 pm EDT / 2:00 pm PDTSAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage...

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results

Individual Patient EAP allows access to efzofitimod for patients who complete the Phase 3 EFZO-FIT study in pulmonary sarcoidosis. Company initiating program based on blinded EFZO-FIT study...

aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT  Clinical Trial Participants

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

We're Hopeful That aTyr Pharma (NASDAQ:LIFE) Will Use Its Cash Wisely

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Watchers	10,933
52-Wk Low	$1.08
52-Wk High	$2.70

Volume	94,946.00
52-Wk High	$2.70
52-Wk Low	$1.08

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.23	--	--	N/A
Q1'24	-$0.25	-$0.23	8.00%	BEAT
Q4'23	-$0.24	-$0.25	-5.04%	MISSED
Q3'23	-$0.23	-$0.20	11.50%	BEAT
Q2'23	-$0.28	-$0.22	21.03%	BEAT

LIFE Atyr Pharma Inc

About

Feed

News

Sentiment

Earnings

Fundamentals